Adaptive Biotechnologies Corp Asset Resilience Ratio
Adaptive Biotechnologies Corp asset resilience ratio. Adaptive Biotechnologies Corp (ADPT) has an Asset Resilience Ratio of 30.52% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ADPT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Adaptive Biotechnologies Corp (2017–2025)
Asset resilience ratio of Adaptive Biotechnologies Corp from 2017 to 2025. This chart shows how Adaptive Biotechnologies Corp's Asset Resilience Ratio has changed over time. Read ADPT total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Adaptive Biotechnologies Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Adaptive Biotechnologies Corp's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $156.49 Million | 30.52% |
| Total Liquid Assets | $156.49 Million | 30.52% |
Asset Resilience Insights
- Very High Liquidity: Adaptive Biotechnologies Corp maintains exceptional liquid asset reserves at 30.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Adaptive Biotechnologies Corp Industry Peers by Asset Resilience Ratio
Compare Adaptive Biotechnologies Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Adaptive Biotechnologies Corp Asset Resilience Ratio by Year (2017–2025)
Adaptive Biotechnologies Corp asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Adaptive Biotechnologies Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.52% | $156.49 Million | $512.74 Million | -1.81pp |
| 2024-12-31 | 32.33% | $174.37 Million | $539.38 Million | -10.22pp |
| 2023-12-31 | 42.55% | $281.34 Million | $661.13 Million | -5.09pp |
| 2022-12-31 | 47.65% | $408.17 Million | $856.62 Million | +24.47pp |
| 2021-12-31 | 23.18% | $214.00 Million | $923.34 Million | -27.42pp |
| 2020-12-31 | 50.59% | $564.83 Million | $1.12 Billion | -2.05pp |
| 2019-12-31 | 52.65% | $480.29 Million | $912.30 Million | +19.59pp |
| 2018-12-31 | 33.06% | $109.99 Million | $332.69 Million | +3.59pp |
| 2017-12-31 | 29.48% | $106.84 Million | $362.49 Million | -- |
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diag… Read more